1-(2-甲氧基乙基)哌啶-4-酮 | 33771-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-甲氧基乙基)哌啶-4-酮
• 中文别名: N-甲氧基乙基-4-哌啶酮
• 英文名称: 1-(2-methoxyethyl)piperidin-4-one
• CAS: 33771-04-9
• 化学式: C₈H₁₅NO₂
• mdl: MFCD09950024
• 分子量: 157.213
• InChiKey: TZBGCFOBLIWBSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-甲氧基乙基)哌啶-4-酮 以91的产率得到[4-[4-(三氟甲基)苯基]苯基]甲胺盐酸盐
  参考文献：
  名称：

  Pyridinone derivatives for treatment of atherosclerosis

  摘要：

  式(I)的化合物是Lp-PLA2酶的抑制剂，可用于治疗，特别是治疗动脉粥样硬化。

  公开号：

  US07235566B2
• 作为产物：
  描述：

  dimethyl 3,3'-(2-methoxyethylazanediyl)dipropanoate 在 sodium methylate 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以31%的产率得到1-(2-甲氧基乙基)哌啶-4-酮
  参考文献：
  名称：

  Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

  摘要：

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.07.051
• 作为试剂：
  描述：

  1-(2-甲氧基乙基)哌啶-4-酮 、 [4-[4-(三氟甲基)苯基]苯基]甲胺盐酸盐 在 1-(2-甲氧基乙基)哌啶-4-酮 作用下， 生成 N-(1-(2-methoxyethyl)piperidin-4-yl)-4-(4-trifluoromethylphenyl)benzylamine
  参考文献：
  名称：

  Pyridinone derivatives for treatment of atherosclerosis

  摘要：

  式(I)的化合物是Lp-PLA2酶的抑制剂，可用于治疗，特别是治疗动脉粥样硬化。

  公开号：

  US07235566B2

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Sheppard S. George

  公开号：US20070203143A1

  公开（公告）日：2007-08-30

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法被披露。
• Pharmaceutical compounds
  申请人：Folkes Adrian

  公开号：US20080076758A1

  公开（公告）日：2008-03-27

  Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化合物Ia和Ib的结构，以及它们的立体异构体、几何异构体、互变异构体、溶剂合物、代谢产物和药学上可接受的盐，可用于抑制包括PI3K在内的脂质激酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用化合物Ia和Ib进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理状况的方法。
• CXCR4 Receptor Antagonists
  申请人：Savory Edward Daniel

  公开号：US20130289020A1

  公开（公告）日：2013-10-31

  Disclosed are compounds that are antagonists of the CXCR4 receptor.

  披露了一些对CXCR4受体具有拮抗作用的化合物。
• [EN] CXCR4 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CXCR4
  申请人：PROXIMAGEN LTD

  公开号：WO2012049277A1

  公开（公告）日：2012-04-19

  The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1 , X, Y and R2 are as defined in the claims.

  式(I)的化合物是CXCR4受体的拮抗剂，其中R1、X、Y和R2如权利要求中所定义。
• QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS
  申请人：ZHANG Hesheng

  公开号：US20090105247A1

  公开（公告）日：2009-04-23

  A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).

  公式（I）的化合物，其药用盐或水合物，以及制备该化合物的方法。一种治疗或预防哺乳动物中由异常蛋白酪氨酸激酶活性引起的生理紊乱的方法，包括向该哺乳动物施用包含公式（I）化合物的药物组合物。